Data as of Dec 09
| +0.01 / +0.45%|
The 3 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 2.50, with a high estimate of 6.00 and a low estimate of 2.50. The median estimate represents a +12.11% increase from the last price of 2.23.
The current consensus among 5 polled investment analysts is to Hold stock in Amicus Therapeutics Inc. This rating has held steady since November, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.